Total Payments
$43,083
2024 Payments
$10,661
Companies
2
Transactions
34
Payment Breakdown by Category
Consulting$31,639 (73.4%)
Research$11,445 (26.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $31,639 | 16 | 73.4% |
| Unspecified | $11,445 | 18 | 26.6% |
Payments by Type
General
$31,639
16 transactions
Research
$11,445
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $39,583 | 32 | $0 (2024) |
| Janssen Research & Development, LLC | $3,500 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,661 | 12 | F. Hoffmann-La Roche AG ($10,661) |
| 2023 | $9,195 | 4 | F. Hoffmann-La Roche AG ($9,195) |
| 2022 | $8,559 | 6 | F. Hoffmann-La Roche AG ($8,559) |
| 2021 | $5,038 | 9 | F. Hoffmann-La Roche AG ($3,538) |
| 2020 | $9,631 | 3 | F. Hoffmann-La Roche AG ($7,631) |
All Payment Transactions
34 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $956.84 | Research |
| Study: Pregnancy and infant outcomes in women with multiple sclerosis receiving ocrelizumab: Analysis of approximately 4,000 pregnancies to date • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $837.24 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $669.79 | Research |
| Study: B-Cell Levels and Breastmilk Transfer in Infants of Lactating Women With Multiple Sclerosis Treated With Ocrelizumab: Primary Results of The Prospective Multicentre, Open-Label Phase IV Study SOPRANINO • Category: Immunology | ||||||
| 08/29/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,412.50 | General |
| 07/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $874.50 | General |
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,295.04 | Research |
| Study: Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,006.72 | Research |
| Study: Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of Over 3000 Pregnancies to Date • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $535.60 | Research |
| Study: Pregnancy and infant outcomes in women with multiple sclerosis receiving ocrelizumab: Analysis of approximately 4000 pregnancies to date • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $468.69 | Research |
| Study: B-cell levels and breastmilk transfer in infants of lactating women with multiple sclerosis treated with ocrelizumab: primary results of the phase IV study SOPRANINO • Category: Immunology | ||||||
| 06/11/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $706.25 | General |
| 03/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $485.59 | Research |
| Study: Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of Over 3000 Pregnancies to Date • Category: Immunology | ||||||
| 03/05/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,412.50 | General |
| 12/31/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,047.29 | Research |
| Study: Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database • Category: Immunology | ||||||
| 10/01/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,260.00 | General |
| 06/30/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $237.70 | Research |
| Study: Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database • Category: Immunology | ||||||
| 01/01/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $5,650.00 | General |
| 12/31/2022 | F. Hoffmann-La Roche AG | OCREVUS (Biological) | — | In-kind items and services | $1,248.11 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE BLINDED, PLACEBO CONTROLLED S • Category: Immunology | ||||||
| 10/01/2022 | F. Hoffmann-La Roche AG | OCREVUS (Biological) | Consulting Fee | Cash or cash equivalent | $1,695.00 | General |
| Category: Immunology | ||||||
| 09/30/2022 | F. Hoffmann-La Roche AG | OCREVUS (Biological) | — | In-kind items and services | $248.38 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE BLINDED, PLACEBO CONTROLLED S • Category: Immunology | ||||||
| 07/01/2022 | F. Hoffmann-La Roche AG | OCREVUS (Biological) | Consulting Fee | Cash or cash equivalent | $1,130.00 | General |
| Category: Immunology | ||||||
| 04/01/2022 | F. Hoffmann-La Roche AG | OCREVUS (Biological) | Consulting Fee | Cash or cash equivalent | $2,260.00 | General |
| Category: Immunology | ||||||
| 01/01/2022 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,977.50 | General |
| 07/15/2021 | F. Hoffmann-La Roche AG | OCREVUS (Biological) | — | In-kind items and services | $592.64 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE BLINDED, PLACEBO CONTROLLED S • Category: Immunology | ||||||
| 07/07/2021 | F. Hoffmann-La Roche AG | OCREVUS (Biological) | — | In-kind items and services | $592.64 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE BLINDED, PLACEBO CONTROLLED S • Category: Immunology | ||||||
| 07/07/2021 | F. Hoffmann-La Roche AG | OCREVUS (Biological) | — | In-kind items and services | $592.64 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE BLINDED, PLACEBO CONTROLLED S • Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE BLINDED, PLACEBO CONTROLLED S | F. Hoffmann-La Roche AG | $3,904 | 8 |
| Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database | F. Hoffmann-La Roche AG | $2,580 | 3 |
| Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of Over 3000 Pregnancies to Date | F. Hoffmann-La Roche AG | $1,492 | 2 |
| Pregnancy and infant outcomes in women with multiple sclerosis receiving ocrelizumab: Analysis of approximately 4,000 pregnancies to date | F. Hoffmann-La Roche AG | $956.84 | 1 |
| Ocrelizumab in Patients with RMS | F. Hoffmann-La Roche AG | $837.24 | 1 |
| B-Cell Levels and Breastmilk Transfer in Infants of Lactating Women With Multiple Sclerosis Treated With Ocrelizumab: Primary Results of The Prospective Multicentre, Open-Label Phase IV Study SOPRANINO | F. Hoffmann-La Roche AG | $669.79 | 1 |
| Pregnancy and infant outcomes in women with multiple sclerosis receiving ocrelizumab: Analysis of approximately 4000 pregnancies to date | F. Hoffmann-La Roche AG | $535.60 | 1 |
| B-cell levels and breastmilk transfer in infants of lactating women with multiple sclerosis treated with ocrelizumab: primary results of the phase IV study SOPRANINO | F. Hoffmann-La Roche AG | $468.69 | 1 |
About Thomas Mcelrath, MD PHD
Thomas Mcelrath, MD PHD is a Maternal & Fetal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871504944.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Thomas Mcelrath, MD PHD has received a total of $43,083 in payments from pharmaceutical and medical device companies, with $10,661 received in 2024. These payments were reported across 34 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($31,639).
Ad
Practice Information
- Specialty Maternal & Fetal Medicine
- Location Boston, MA
- Active Since 08/11/2006
- Last Updated 06/24/2012
- Taxonomy Code 207VM0101X
- Entity Type Individual
- NPI Number 1871504944
Products in Payments
- OCREVUS (Biological) $17,750
- Ocrevus (Biological) $7,541
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Maternal & Fetal Medicine Doctors in Boston
Dr. Scott Shainker, Do, DO
Maternal & Fetal Medicine — Payments: $7,613
Maternal & Fetal Medicine $7,613
Kolawole Oyelese, M.d, M.D
Maternal & Fetal Medicine — Payments: $6,737
Maternal & Fetal Medicine $6,737
Dr. Laura Riley, Md, MD
Maternal & Fetal Medicine — Payments: $6,187
Maternal & Fetal Medicine $6,187
Julian Robinson, Md, MD
Maternal & Fetal Medicine — Payments: $4,224
Maternal & Fetal Medicine $4,224
Glenn Markenson, Md, MD
Maternal & Fetal Medicine — Payments: $1,638
Maternal & Fetal Medicine $1,638
Curtis Cetrulo, M.d, M.D
Maternal & Fetal Medicine — Payments: $502.32
Maternal & Fetal Medicine $502.32